Trials that involve new drugs being compared to existing versions could let inferior treatments slip through.
It’s much easier to get a medical device approved than to bring a new drug to market. Should that change?
Critics say a certain type of statement allowed on food labels could mislead—rather than inform—consumers.
An underdiagnosed condition gets its first new drug in 40 years.
Will consumers continue to have the power to question a drug’s safety?
The United States is launching a database to remedy a lack of transparency in clinical trial results.
The testing of artificial blood has sparked controversy over individual rights.
No-name drugs may be cheaper than brand names, but they have some drawbacks as well.
Understanding the patient’s genetic makeup is leading to better, more precisely targeted treatments.
No Articles Found.